FDA (CDER)
GUIDANCE FINAL
Pulmonary Tuberculosis: Developing Drugs for Treatment
Published: 5/8/2026Detected: 5/8/2026
Summary preview
Developing Drugs for the treatment of pulmonary tuberculosis outlines FDA’s expectations for how sponsors should design and support drug development, including clinical evidence generation, benefit-risk assessment, and…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
respiratory
clinical
safety
labeling
quality
#pulmonary tuberculosis
#drug development
#clinical endpoints
#safety monitoring
#benefit-risk
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
- Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
- Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
- Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
- Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026